[미국특허]
Long-acting polypeptides and methods of producing and administering same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/18
C07K-014/505
C07K-014/59
C07K-014/61
C07K-014/555
출원번호
US-0555258
(2014-11-26)
등록번호
US-9828417
(2017-11-28)
발명자
/ 주소
Fima, Udi Eyal
Hart, Gili
출원인 / 주소
OPKO Biologics Ltd.
대리인 / 주소
Cohen, Mark
인용정보
피인용 횟수 :
0인용 특허 :
80
초록▼
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
대표청구항▼
1. A method of treating an erythropoietin (EPO)-associated condition, wherein said EPO-associated condition is anemia, said method comprising administering to a subject a therapeutically effective amount of a polypeptide consisting of a chorionic gonadotropin carboxy terminal peptide (CTP) modified
1. A method of treating an erythropoietin (EPO)-associated condition, wherein said EPO-associated condition is anemia, said method comprising administering to a subject a therapeutically effective amount of a polypeptide consisting of a chorionic gonadotropin carboxy terminal peptide (CTP) modified erythropoietin (EPO), said CTP-modified EPO polypeptide consisting of one chorionic gonadotropin carboxy terminal peptide (CTP) attached to the amino terminus of said EPO, and two chorionic gonadotropin CTPs attached to the carboxy terminus of said EPO, or said CTP-modified EPO polypeptide consisting of one chorionic gonadotropin carboxy terminal peptide (CTP) attached to the amino terminus of said EPO, and two chorionic gonadotropin CTPs attached to the carboxy terminus of said EPO, and a signal peptide attached to the amino terminal CTP. 2. The method of claim 1, wherein the sequence of at least one chorionic gonadotrophin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:17 and SEQ ID NO:18. 3. The method of claim 1, wherein at least one chorionic gonadotrophin carboxy terminal peptide is truncated. 4. The method of claim 1, wherein said EPO is glycosylated. 5. The method of claim 1, wherein said EPO is non-glycosylated. 6. The method of claim 1, wherein at least one chorionic gonadotrophin carboxy terminal peptide is glycosylated. 7. The method of claim 1, wherein the amino acid sequence of said CTP-modified EPO polypeptide is set forth in SEQ ID NO: 51. 8. The method of claim 1, wherein the amino acid sequence of said CTP-modified EPO polypeptide is set forth in SEQ ID NO: 3. 9. The method of claim 1, wherein the amino acid sequence of said signal peptide comprises the sequence set forth in SEQ ID NO: 19. 10. The method of claim 1, wherein said anemia comprises tumor-associated anemia, aplastic anemia, autoimmune hemolytic anemia, bone marrow transplantation, Churg-Strauss syndrome, Diamond Blackfan anemia, Fanconi's anemia, Felty syndrome, graft versus host disease, hematopoietic stem cell transplantation, hemolytic uremic syndrome, myelodysplasic syndrome, nocturnal paroxysmal hemoglobinuria, osteomyelofibrosis, pancytopenia, pure red-cell aplasia, purpura Schoenlein-Henoch, sideroblastic anemia, refractory anemia with excess of blasts, rheumatoid arthritis, Shwachman syndrome, sickle cell disease, thalassemia major, thalassemia minor, or thrombocytopenic purpura. 11. A method of stimulating erythropoiesis, said method comprising administering to a subject a therapeutically effective amount of a polypeptide consisting of a chorionic gonadotropin carboxy terminal peptide (CTP) modified erythropoietin (EPO), said CTP-modified EPO consisting of one chorionic gonadotropin carboxy terminal peptide (CTP) attached to the amino terminus of said EPO, and two chorionic gonadotropin CTPs attached to the carboxy terminus of said EPO, and wherein the amino acid sequence of said CTP-modified EPO consists of the sequence set forth in SEQ ID NO: 51, or wherein said CTP-modified EPO polypeptide consist of a chorionic gonadotropin carboxy terminal peptide (CTP) modified erythropoietin (EPO), said CTP-modified EPO polypeptide consisting of one chorionic gonadotropin carboxy terminal peptide (CTP) attached to the amino terminus of said EPO, and two chorionic gonadotropin CTPs attached to the carboxy terminus of said EPO, and a signal peptide attached to the amino terminal CTP, and wherein the amino acid sequence of said CTP-modified EPO consists of the sequence set forth in SEQ ID NO: 3. 12. The method of claim 11, wherein the amino acid sequence of said signal peptide comprises the sequence set forth in SEQ ID NO: 19. 13. The method of claim 11, wherein said EPO is glycosylated. 14. The method of claim 11, wherein said EPO is non-glycosylated. 15. The method of claim 11, wherein at least one chorionic gonadotrophin carboxy terminal peptide is glycosylated.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Lee, Dong-Eok; Oh, Myung-Suk; Kim, Ki-Wan; Chung, Bo-Sup; Ha, Byung-Jhip; Park, Ji-Sook, Fusion protein having the enhanced in vivo activity of erythropoietin.
DeFrees, Shawn; Zopf, David A.; Bayer, Robert J.; Hakes, David James; Bowe, Caryn L.; Chen, Xi, Glycopegylation methods and proteins/peptides produced by the methods.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Klima,Horst; Lehmann,Paul; Roeddiger,Ralf; Walter Matsui,Ruth, Method of treating disturbances of iron distribution in inflammatory intestinal diseases.
Martinez, Alexa L; Sherman, Merry R; Saifer, Mark G. P.; Williams, L. David, Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof.
Boime Irving ; Menahem David Ben, Single chain glycoprotein hormones comprising two .beta. and one .alpha. subunits and recombinant production thereof.
Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-Da (Oakland CA), Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins.
Selden Richard F. ; Borowski Marianne ; Gillispie Frances P. ; Kinoshita Carol M. ; Treco Douglas A. ; Williams Melanie D., Tranfected human cells expressing human .alpha.-galactosidase A protein.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.